

TDMS No. 97003 - 08

**P05: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS
ABRIDGED) (a)**

Date Report Reqsted: 08/21/2007

Test Type: CHRONIC

1,2-Dibromo-2,4-dicyanobutane

Time Report Reqsted: 13:25:49

Route: SKIN APPLICATION

CAS Number: 35691-65-7

First Dose M/F: 06/25/02 / 06/24/02

Species/Strain: MICE/B6C3F1

Lab: BAT

F_1.Rev.1_M3

C Number: C97003D
Lock Date: 01/31/2005
Cage Range: ALL
Date Range: ALL
Reasons For Removal: ALL
Removal Date Range: ALL
Treatment Groups: Include ALL
TDMSE Version: 1.8.0

Test Type: CHRONIC

1,2-Dibromo-2,4-dicyanobutane

Time Report Requested: 13:25:49

Route: SKIN APPLICATION

CAS Number: 35691-65-7

First Dose M/F: 06/25/02 / 06/24/02

Species/Strain: MICE/B6C3F1

Lab: BAT

B6C3F1 MICE MALE	0 MG/KG	0.6 MG/KG	2 MG/KG	6 MG/KG
Disposition Summary				
Animals Initially in Study	50	50	50	50
Early Deaths				
Accidently Killed		1		
Moribund Sacrifice	8	12	8	7
Natural Death	7	7	3	3
Survivors				
Moribund Sacrifice	1			
Terminal Sacrifice	34	30	39	40
Animals Examined Microscopically	50	50	50	50

ALIMENTARY SYSTEM

Esophagus	(50)	(50)	(50)	(50)
Gallbladder	(49)	(49)	(48)	(49)
Intestine Large, Cecum	(50)	(50)	(50)	(50)
Intestine Large, Colon	(50)	(50)	(50)	(50)
Intestine Large, Rectum	(50)	(50)	(50)	(50)
Intestine Small, Duodenum	(50)	(50)	(50)	(50)
Intestine Small, Ileum	(50)	(49)	(50)	(50)
Intestine Small, Jejunum	(50)	(50)	(50)	(50)
Carcinoma			1 (2%)	
Fibrous Histiocytoma, Metastatic, Lymph Node, Mesenteric	1 (2%)			
Liver	(50)	(50)	(50)	(50)
Fibrous Histiocytoma, Metastatic, Lymph Node, Mesenteric	1 (2%)			
Hemangiosarcoma	1 (2%)	3 (6%)		1 (2%)
Hemangiosarcoma, Multiple		3 (6%)	1 (2%)	
Hepatoblastoma	2 (4%)	1 (2%)	2 (4%)	2 (4%)
Hepatocellular Adenoma	14 (28%)	17 (34%)	11 (22%)	10 (20%)
Hepatocellular Adenoma, Multiple	21 (42%)	18 (36%)	22 (44%)	17 (34%)
Hepatocellular Carcinoma	17 (34%)	7 (14%)	11 (22%)	3 (6%)
Hepatocellular Carcinoma, Multiple		3 (6%)	3 (6%)	7 (14%)
Hepatocholangiocarcinoma		2 (4%)		1 (2%)
Mesentery	(10)	(3)	(4)	(2)
Carcinoma, Metastatic, Uncertain				1 (50%)

a - Number of animals examined microscopically at site and number of animals with lesion

Test Type: CHRONIC

1,2-Dibromo-2,4-dicyanobutane

Time Report Requested: 13:25:49

Route: SKIN APPLICATION

CAS Number: 35691-65-7

First Dose M/F: 06/25/02 / 06/24/02

Species/Strain: MICE/B6C3F1

Lab: BAT

B6C3F1 MICE MALE	0 MG/KG	0.6 MG/KG	2 MG/KG	6 MG/KG
Primary Site				
Hemangiosarcoma	1 (10%)			
Hepatocellular Carcinoma, Metastatic, Liver			1 (25%)	
Pancreas	(50)	(50)	(50)	(50)
Hepatocholangiocarcinoma, Metastatic, Liver		1 (2%)		
Salivary Glands	(50)	(50)	(50)	(50)
Parotid Gland, Adenoma			1 (2%)	
Stomach, Forestomach	(50)	(50)	(50)	(50)
Squamous Cell Carcinoma		1 (2%)		
Squamous Cell Papilloma				1 (2%)
Stomach, Glandular	(50)	(50)	(50)	(50)
Tooth	(31)	(32)	(37)	(35)
CARDIOVASCULAR SYSTEM				
Blood Vessel	(50)	(50)	(50)	(50)
Hemangiosarcoma			1 (2%)	
Adventitia, Alveolar/Bronchiolar Carcinoma, Metastatic, Lung		1 (2%)		
Adventitia, Hepatocholangiocarcinoma, Metastatic, Liver		1 (2%)		
Aorta, Thymoma Malignant, Metastatic, Thymus	1 (2%)			
Heart	(50)	(50)	(50)	(50)
Alveolar/Bronchiolar Carcinoma, Metastatic, Lung		1 (2%)		1 (2%)
Hemangiosarcoma		1 (2%)		
ENDOCRINE SYSTEM				
Adrenal Cortex	(50)	(50)	(50)	(50)
Alveolar/Bronchiolar Carcinoma, Metastatic, Lung		1 (2%)		
Hepatocellular Carcinoma, Metastatic, Liver		1 (2%)		
Subcapsular, Adenoma	6 (12%)	2 (4%)	2 (4%)	4 (8%)
Zona Fasciculata, Adenoma			1 (2%)	

a - Number of animals examined microscopically at site and number of animals with lesion

Test Type: CHRONIC

1,2-Dibromo-2,4-dicyanobutane

Time Report Requested: 13:25:49

Route: SKIN APPLICATION

CAS Number: 35691-65-7

First Dose M/F: 06/25/02 / 06/24/02

Species/Strain: MICE/B6C3F1

Lab: BAT

B6C3F1 MICE MALE	0 MG/KG	0.6 MG/KG	2 MG/KG	6 MG/KG
Adrenal Medulla	(50)	(49)	(50)	(50)
Alveolar/Bronchiolar Carcinoma, Metastatic, Lung		1 (2%)		
Pheochromocytoma Benign		1 (2%)		
Pheochromocytoma Malignant	1 (2%)			
Islets, Pancreatic	(50)	(50)	(50)	(50)
Adenoma		1 (2%)	1 (2%)	2 (4%)
Parathyroid Gland	(42)	(40)	(43)	(41)
Pituitary Gland	(50)	(50)	(49)	(50)
Pars Intermedia, Adenoma		1 (2%)		
Thyroid Gland	(50)	(50)	(50)	(50)
Follicular Cell, Adenoma		1 (2%)	1 (2%)	
Follicular Cell, Carcinoma			1 (2%)	
GENERAL BODY SYSTEM				
None				
GENITAL SYSTEM				
Coagulating Gland	(0)	(1)	(2)	(1)
Epididymis	(50)	(50)	(50)	(50)
Fibrous Histiocytoma, Metastatic, Lymph Node, Mesenteric	1 (2%)			
Penis	(0)	(2)	(0)	(0)
Squamous Cell Carcinoma		1 (50%)		
Preputial Gland	(50)	(50)	(50)	(50)
Prostate	(50)	(50)	(50)	(50)
Seminal Vesicle	(50)	(50)	(50)	(50)
Testes	(50)	(50)	(50)	(50)
Bilateral, Interstitial Cell, Adenoma			1 (2%)	
Interstitial Cell, Adenoma	2 (4%)	2 (4%)	1 (2%)	2 (4%)
HEMATOPOIETIC SYSTEM				
Bone Marrow	(50)	(50)	(50)	(50)
Hemangiosarcoma	1 (2%)	4 (8%)	1 (2%)	2 (4%)
Lymph Node	(0)	(1)	(3)	(1)
Lymph Node, Mandibular	(50)	(50)	(50)	(50)

a - Number of animals examined microscopically at site and number of animals with lesion

Test Type: CHRONIC

1,2-Dibromo-2,4-dicyanobutane

Time Report Requested: 13:25:49

Route: SKIN APPLICATION

CAS Number: 35691-65-7

First Dose M/F: 06/25/02 / 06/24/02

Species/Strain: MICE/B6C3F1

Lab: BAT

B6C3F1 MICE MALE	0 MG/KG	0.6 MG/KG	2 MG/KG	6 MG/KG
Lymph Node, Mesenteric	(50)	(50)	(50)	(50)
Fibrous Histiocytoma	1 (2%)			
Spleen	(50)	(49)	(50)	(50)
Fibrous Histiocytoma, Metastatic, Lymph Node, Mesenteric	1 (2%)			
Hemangiosarcoma	1 (2%)	2 (4%)	2 (4%)	1 (2%)
Thymus	(47)	(48)	(46)	(46)
Alveolar/Bronchiolar Carcinoma, Metastatic, Lung		1 (2%)		
Hepatocholangiocarcinoma, Metastatic, Liver		1 (2%)		
Thymoma Malignant	1 (2%)			
INTEGUMENTARY SYSTEM				
Skin	(50)	(50)	(50)	(50)
Squamous Cell Carcinoma		1 (2%)		
Site Of Application, Alveolar/Bronchiolar Carcinoma, Metastatic, Lung				1 (2%)
Site Of Application, Hemangiosarcoma				1 (2%)
Subcutaneous Tissue, Fibrosarcoma				1 (2%)
Subcutaneous Tissue, Hemangiosarcoma	2 (4%)	1 (2%)		
MUSCULOSKELETAL SYSTEM				
Bone	(50)	(50)	(50)	(50)
Squamous Cell Carcinoma, Metastatic, Skin		1 (2%)		
Skeletal Muscle	(0)	(0)	(1)	(0)
Hemangiosarcoma			1 (100%)	
NERVOUS SYSTEM				
Brain	(50)	(50)	(50)	(50)
Squamous Cell Carcinoma, Metastatic, Skin		1 (2%)		
Spinal Cord	(0)	(0)	(0)	(1)
Meninges, Hemangiosarcoma,				1 (100%)

a - Number of animals examined microscopically at site and number of animals with lesion

Test Type: CHRONIC

1,2-Dibromo-2,4-dicyanobutane

Time Report Requested: 13:25:49

Route: SKIN APPLICATION

CAS Number: 35691-65-7

First Dose M/F: 06/25/02 / 06/24/02

Species/Strain: MICE/B6C3F1

Lab: BAT

B6C3F1 MICE MALE	0 MG/KG	0.6 MG/KG	2 MG/KG	6 MG/KG
, Spleen				
RESPIRATORY SYSTEM				
Lung	(50)	(50)	(50)	(50)
Alveolar/Bronchiolar Adenoma	9 (18%)	6 (12%)	14 (28%)	6 (12%)
Alveolar/Bronchiolar Adenoma, Multiple	1 (2%)		1 (2%)	1 (2%)
Alveolar/Bronchiolar Carcinoma	6 (12%)	5 (10%)	4 (8%)	1 (2%)
Alveolar/Bronchiolar Carcinoma, Metastatic, Lung		2 (4%)		1 (2%)
Alveolar/Bronchiolar Carcinoma, Multiple		2 (4%)		1 (2%)
Fibrous Histiocytoma, Metastatic, Lymph Node, Mesenteric	1 (2%)			
Hepatocellular Carcinoma, Metastatic, Liver	9 (18%)	3 (6%)	8 (16%)	2 (4%)
Hepatocholangiocarcinoma, Metastatic, Liver		2 (4%)		
Squamous Cell Carcinoma, Metastatic, Skin		1 (2%)		
Thymoma Malignant, Metastatic, Thymus	1 (2%)			
Alveolar Epithelium, Alveolar/Bronchiolar Adenoma, Multiple			1 (2%)	
Follicular Cell, Carcinoma, Metastatic, Thyroid Gland			1 (2%)	
Nose	(50)	(50)	(50)	(50)
Trachea	(50)	(50)	(50)	(50)
SPECIAL SENSES SYSTEM				
Eye	(50)	(50)	(50)	(50)
Harderian Gland	(50)	(50)	(50)	(50)
Adenoma	7 (14%)	6 (12%)	5 (10%)	6 (12%)
Carcinoma			2 (4%)	
URINARY SYSTEM				
Kidney	(50)	(50)	(50)	(50)
Alveolar/Bronchiolar Carcinoma, Metastatic, Lung		1 (2%)		

a - Number of animals examined microscopically at site and number of animals with lesion

Test Type: CHRONIC

1,2-Dibromo-2,4-dicyanobutane

Time Report Requested: 13:25:49

Route: SKIN APPLICATION

CAS Number: 35691-65-7

First Dose M/F: 06/25/02 / 06/24/02

Species/Strain: MICE/B6C3F1

Lab: BAT

B6C3F1 MICE MALE	0 MG/KG	0.6 MG/KG	2 MG/KG	6 MG/KG
Hemangioma			1 (2%)	
Hepatocellular Carcinoma, Metastatic, Liver			1 (2%)	
Hepatocholangiocarcinoma, Metastatic, Liver		2 (4%)		
Renal Tubule, Adenoma			2 (4%)	
Urinary Bladder	(50)	(50)	(50)	(50)
SYSTEMIC LESIONS				
Multiple Organs	*(50)	*(50)	*(50)	*(50)
Histiocytic Sarcoma			2 (4%)	
Lymphoma Malignant	1 (2%)	2 (4%)	3 (6%)	3 (6%)

a - Number of animals examined microscopically at site and number of animals with lesion

* Number of animals with any tissue examined microscopically

Test Type: CHRONIC

1,2-Dibromo-2,4-dicyanobutane

Time Report Requested: 13:25:49

Route: SKIN APPLICATION

CAS Number: 35691-65-7

First Dose M/F: 06/25/02 / 06/24/02

Species/Strain: MICE/B6C3F1

Lab: BAT

B6C3F1 MICE MALE	0 MG/KG	0.6 MG/KG	2 MG/KG	6 MG/KG
Tumor Summary for Males				
Total Animals with Primary Neoplasms (b)	45	47	48	43
Total Primary Neoplasms	95	94	100	73
Total Animals with Benign Neoplasms	40	40	41	37
Total Benign Neoplasms	60	55	65	49
Total Animals with Malignant Neoplasms	27	30	32	20
Total Malignant Neoplasms	35	39	35	24
Total Animals with Metastatic Neoplasms	10	8	10	4
Total Metastatic Neoplasms	16	22	11	7
Total Animals with Malignant Neoplasms Uncertain Primary Site				1
Total Animals with Neoplasms Uncertain-Benign or Malignant				
Total Uncertain Neoplasms				

*** END OF MALE ***

a - Number of animals examined microscopically at site and number of animals with lesion

b - Primary tumors: all tumors except metastatic tumors

Test Type: CHRONIC

1,2-Dibromo-2,4-dicyanobutane

Time Report Requested: 13:25:49

Route: SKIN APPLICATION

CAS Number: 35691-65-7

First Dose M/F: 06/25/02 / 06/24/02

Species/Strain: MICE/B6C3F1

Lab: BAT

B6C3F1 MICE FEMALE	0 MG/KG	0.6 MG/KG	2 MG/KG	6 MG/KG
Disposition Summary				
Animals Initially in Study	50	50	50	50
Early Deaths				
Moribund Sacrifice	10	11	14	11
Natural Death	7	3	6	4
Survivors				
Natural Death		1		
Terminal Sacrifice	33	35	30	35
Animals Examined Microscopically	50	50	50	50
ALIMENTARY SYSTEM				
Esophagus	(50)	(50)	(50)	(50)
Gallbladder	(50)	(49)	(50)	(50)
Intestine Small, Duodenum	(50)	(50)	(50)	(50)
Carcinoma			1 (2%)	
Intestine Small, Jejunum	(50)	(50)	(50)	(50)
Hepatocellular Carcinoma, Metastatic, Liver				1 (2%)
Liver	(50)	(50)	(50)	(50)
Fibrous Histiocytoma	1 (2%)			
Hemangiosarcoma	1 (2%)		1 (2%)	1 (2%)
Hepatoblastoma	1 (2%)			
Hepatocellular Adenoma	6 (12%)	12 (24%)	16 (32%)	15 (30%)
Hepatocellular Adenoma, Multiple	25 (50%)	13 (26%)	9 (18%)	6 (12%)
Hepatocellular Carcinoma	8 (16%)	5 (10%)	6 (12%)	2 (4%)
Hepatocellular Carcinoma, Multiple				1 (2%)
Mesentery	(10)	(9)	(6)	(10)
Hepatocellular Carcinoma, Metastatic, Liver				1 (10%)
Sarcoma				1 (10%)
Pancreas	(50)	(50)	(50)	(50)
Fibrous Histiocytoma, Metastatic, Lymph Node, Mesenteric		1 (2%)		
Salivary Glands	(50)	(50)	(50)	(50)
Stomach, Forestomach	(50)	(50)	(50)	(50)
Squamous Cell Papilloma	1 (2%)	1 (2%)		1 (2%)

a - Number of animals examined microscopically at site and number of animals with lesion

Test Type: CHRONIC

1,2-Dibromo-2,4-dicyanobutane

Time Report Requested: 13:25:49

Route: SKIN APPLICATION

CAS Number: 35691-65-7

First Dose M/F: 06/25/02 / 06/24/02

Species/Strain: MICE/B6C3F1

Lab: BAT

B6C3F1 MICE FEMALE	0 MG/KG	0.6 MG/KG	2 MG/KG	6 MG/KG
Stomach, Glandular	(50)	(50)	(50)	(50)
Tooth	(3)	(4)	(4)	(1)
CARDIOVASCULAR SYSTEM				
Blood Vessel	(50)	(50)	(50)	(50)
Heart	(50)	(50)	(50)	(50)
Fibrosarcoma, Metastatic, Skin		1 (2%)		
Fibrous Histiocytoma, Metastatic, Lymph Node, Mesenteric		1 (2%)		
Osteosarcoma, Metastatic, Bone	1 (2%)			
ENDOCRINE SYSTEM				
Adrenal Cortex	(50)	(50)	(50)	(50)
Hepatocellular Carcinoma, Metastatic, Liver				1 (2%)
Capsule, Fibrous Histiocytoma, Metastatic, Lymph Node, Mesenteric		1 (2%)		
Subcapsular, Adenoma			1 (2%)	
Adrenal Medulla	(50)	(50)	(50)	(50)
Pheochromocytoma Benign	2 (4%)	1 (2%)		1 (2%)
Islets, Pancreatic	(50)	(50)	(50)	(50)
Adenoma	1 (2%)			2 (4%)
Parathyroid Gland	(38)	(40)	(40)	(41)
Pituitary Gland	(50)	(50)	(50)	(50)
Pars Distalis, Adenoma	5 (10%)	7 (14%)	8 (16%)	5 (10%)
Pars Intermedia, Adenoma	1 (2%)	2 (4%)		
Thyroid Gland	(50)	(50)	(50)	(50)
Follicular Cell, Adenoma		1 (2%)	1 (2%)	
Follicular Cell, Carcinoma		1 (2%)	1 (2%)	1 (2%)
GENERAL BODY SYSTEM				
None				
GENITAL SYSTEM				

a - Number of animals examined microscopically at site and number of animals with lesion

Test Type: CHRONIC

1,2-Dibromo-2,4-dicyanobutane

Time Report Requested: 13:25:49

Route: SKIN APPLICATION

CAS Number: 35691-65-7

First Dose M/F: 06/25/02 / 06/24/02

Species/Strain: MICE/B6C3F1

Lab: BAT

B6C3F1 MICE FEMALE	0 MG/KG	0.6 MG/KG	2 MG/KG	6 MG/KG
Clitoral Gland	(50)	(49)	(50)	(50)
Ovary	(50)	(50)	(50)	(50)
Cystadenoma	3 (6%)	2 (4%)		3 (6%)
Fibrous Histiocytoma	1 (2%)			
Granulosa Cell Tumor Benign		1 (2%)	1 (2%)	
Hemangiosarcoma		1 (2%)	1 (2%)	
Uterus	(50)	(50)	(50)	(50)
Hemangioma				2 (4%)
Hemangiosarcoma			1 (2%)	
Polyp Stromal	1 (2%)	1 (2%)	3 (6%)	2 (4%)
Sarcoma Stromal			1 (2%)	
Vagina	(0)	(0)	(3)	(0)
Fibrosarcoma			1 (33%)	
Hemangiosarcoma			1 (33%)	
Squamous Cell Carcinoma			1 (33%)	
HEMATOPOIETIC SYSTEM				
Bone Marrow	(50)	(50)	(50)	(50)
Hemangiosarcoma				1 (2%)
Lymph Node	(8)	(6)	(6)	(4)
Lumbar, Fibrous Histiocytoma	1 (13%)			
Mediastinal, Fibrosarcoma, Metastatic, Skin		1 (17%)		
Mediastinal, Fibrous Histiocytoma	1 (13%)			
Lymph Node, Mandibular	(50)	(50)	(50)	(50)
Fibrous Histiocytoma	1 (2%)			
Lymph Node, Mesenteric	(50)	(50)	(50)	(50)
Fibrous Histiocytoma	1 (2%)	1 (2%)		
Spleen	(50)	(50)	(50)	(50)
Fibrous Histiocytoma	1 (2%)			
Hemangiosarcoma			1 (2%)	
Thymus	(47)	(47)	(48)	(50)
Fibrous Histiocytoma, Metastatic, Lymph Node, Mesenteric		1 (2%)		
Thymoma Malignant	1 (2%)		1 (2%)	
INTEGUMENTARY SYSTEM				

a - Number of animals examined microscopically at site and number of animals with lesion

Test Type: CHRONIC

1,2-Dibromo-2,4-dicyanobutane

Time Report Requested: 13:25:49

Route: SKIN APPLICATION

CAS Number: 35691-65-7

First Dose M/F: 06/25/02 / 06/24/02

Species/Strain: MICE/B6C3F1

Lab: BAT

B6C3F1 MICE FEMALE	0 MG/KG	0.6 MG/KG	2 MG/KG	6 MG/KG
Mammary Gland	(50)	(49)	(50)	(50)
Skin	(50)	(50)	(50)	(50)
Basal Cell Carcinoma	1 (2%)			
Subcutaneous Tissue, Fibrosarcoma		1 (2%)		2 (4%)
Subcutaneous Tissue, Hemangiosarcoma		1 (2%)		
Subcutaneous Tissue, Sarcoma		1 (2%)	2 (4%)	
Subcutaneous Tissue, Sarcoma, Multiple	1 (2%)			
Subcutaneous Tissue, Schwannoma Malignant	1 (2%)			
MUSCULOSKELETAL SYSTEM				
Bone	(50)	(50)	(50)	(50)
Carcinoma, Metastatic, Harderian Gland			1 (2%)	
Osteosarcoma	1 (2%)			
Schwannoma Malignant, Metastatic, Brain	1 (2%)			
Skeletal Muscle	(1)	(1)	(1)	(1)
Hepatocellular Carcinoma, Metastatic, Liver	1 (100%)	1 (100%)		1 (100%)
NERVOUS SYSTEM				
Brain	(50)	(50)	(50)	(50)
Schwannoma Malignant	1 (2%)			
RESPIRATORY SYSTEM				
Lung	(50)	(50)	(50)	(50)
Alveolar/Bronchiolar Adenoma	2 (4%)		2 (4%)	2 (4%)
Alveolar/Bronchiolar Carcinoma	3 (6%)	2 (4%)	4 (8%)	1 (2%)
Alveolar/Bronchiolar Carcinoma, Metastatic, Lung	1 (2%)			
Carcinoma, Metastatic, Harderian Gland			1 (2%)	
Fibrosarcoma, Metastatic, Skin		1 (2%)		
Fibrous Histiocytoma	1 (2%)			
Fibrous Histiocytoma, Metastatic, Lymph Node, Mesenteric		1 (2%)		

a - Number of animals examined microscopically at site and number of animals with lesion

Test Type: CHRONIC

1,2-Dibromo-2,4-dicyanobutane

Time Report Requested: 13:25:49

Route: SKIN APPLICATION

CAS Number: 35691-65-7

First Dose M/F: 06/25/02 / 06/24/02

Species/Strain: MICE/B6C3F1

Lab: BAT

B6C3F1 MICE FEMALE	0 MG/KG	0.6 MG/KG	2 MG/KG	6 MG/KG
Hemangiosarcoma				1 (2%)
Hepatocellular Carcinoma, Metastatic, Liver	1 (2%)	3 (6%)	2 (4%)	2 (4%)
Hepatocellular Carcinoma, Metastatic, Lung	1 (2%)			
Osteosarcoma, Metastatic, Bone Sarcoma, Metastatic, Skin	1 (2%)		1 (2%)	
Nose	(50)	(50)	(50)	(50)
Trachea	(50)	(50)	(50)	(50)
SPECIAL SENSES SYSTEM				
Eye	(50)	(50)	(50)	(50)
Harderian Gland	(50)	(50)	(50)	(50)
Adenoma	6 (12%)	9 (18%)	7 (14%)	5 (10%)
Carcinoma	2 (4%)	1 (2%)	1 (2%)	
URINARY SYSTEM				
Kidney	(50)	(50)	(50)	(50)
Urinary Bladder	(50)	(50)	(50)	(50)
Fibrous Histiocytoma, Metastatic, Lymph Node, Mesenteric		1 (2%)		
SYSTEMIC LESIONS				
Multiple Organs	*(50)	*(50)	*(50)	*(50)
Histiocytic Sarcoma	1 (2%)	1 (2%)	5 (10%)	1 (2%)
Lymphoma Malignant	14 (28%)	9 (18%)	7 (14%)	7 (14%)

a - Number of animals examined microscopically at site and number of animals with lesion

* Number of animals with any tissue examined microscopically

Test Type: CHRONIC

1,2-Dibromo-2,4-dicyanobutane

Time Report Requested: 13:25:49

Route: SKIN APPLICATION

CAS Number: 35691-65-7

First Dose M/F: 06/25/02 / 06/24/02

Species/Strain: MICE/B6C3F1

Lab: BAT

B6C3F1 MICE FEMALE	0 MG/KG	0.6 MG/KG	2 MG/KG	6 MG/KG
--------------------	---------	-----------	---------	---------

Tumor Summary for Females

Total Animals with Primary Neoplasms (b)	46	45	44	38
Total Primary Neoplasms	97	74	84	63
Total Animals with Benign Neoplasms	39	33	35	31
Total Benign Neoplasms	53	50	48	44
Total Animals with Malignant Neoplasms	31	20	32	17
Total Malignant Neoplasms	44	24	36	19
Total Animals with Metastatic Neoplasms	6	5	3	2
Total Metastatic Neoplasms	7	13	5	6
Total Animals with Malignant Neoplasms Uncertain Primary Site				
Total Animals with Neoplasms Uncertain-Benign or Malignant				
Total Uncertain Neoplasms				

*** END OF REPORT ***

a - Number of animals examined microscopically at site and number of animals with lesion

b - Primary tumors: all tumors except metastatic tumors